Boston Scientific (NYSE:BSX) Hits New 52-Week Low Following Analyst Downgrade

Key Points

• Boston Scientific shares hit a new 52-week low after Wall Street Zen downgraded the stock to a hold, trading as low as $65.20 (last ~$64.41) amid a ~7.3% drop, while several firms cut price targets; the consensus remains a Moderate Buy with a $104.36 target.
• Positive clinical readouts—CHAMPION‑AF for the Watchman FLX and HI‑PEITHO for EKOS—could broaden device adoption and revenue potential, with Q1 results due April 22 as the next major catalyst.
• Insider and legal developments: CEO Michael F. Mahoney sold 160,901 shares (reducing his stake ~10.2%), and multiple law firms have issued investor litigation notices, adding potential legal risk for management and shareholders.

Boston Scientific Corporation (NYSE:BSX - Get Free Report)'s share price hit a new 52-week low on Monday after Wall Street Zen downgraded the stock from a buy rating to a hold rating. The company traded as low as $65.20 and last traded at $64.4060, with a volume of 451819 shares changing hands. The stock had previously closed at $69.17.

Several other equities research analysts have also issued reports on BSX. Royal Bank Of Canada lowered their price target on shares of Boston Scientific from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Thursday, February 5th. Oppenheimer decreased their target price on shares of Boston Scientific from $125.00 to $100.00 and set an "outperform" rating on the stock in a research report on Friday, January 16th. Evercore lowered their target price on shares of Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. Citigroup dropped their price target on shares of Boston Scientific from $102.00 to $94.00 and set a "buy" rating for the company in a research report on Wednesday, March 11th. Finally, Morgan Stanley cut their price target on shares of Boston Scientific from $130.00 to $118.00 and set an "overweight" rating for the company in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.36.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.34% of the company's stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Late‑breaking CHAMPION‑AF trial: WATCHMAN FLX met all primary and secondary safety and efficacy endpoints vs. NOACs, with superior bleeding protection — supports broader LAAC adoption and reimbursement upside. CHAMPION-AF PR Newswire
• Positive Sentiment: HI‑PEITHO/EKOS trial: EKOS plus anticoagulation was superior to anticoagulation alone for intermediate‑risk pulmonary embolism — positive clinical outcome that could expand EKOS utilization and revenue potential. HI-PEITHO PR Newswire
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy with a $97 PT and Raymond James reaffirmed Outperform with an $88 PT — both imply meaningful upside from current levels and may drive investor interest. Needham/Benzinga Raymond James/Finviz
• Positive Sentiment: TD Cowen maintained a Buy on Watchman FLX (PT $100), reinforcing bullish views on LAAC market growth and the device’s trial momentum. TD Cowen/TipRanks
• Neutral Sentiment: Q1 earnings setup and timing: Boston Scientific scheduled its Q1 2026 results conference call for April 22; analysts expect single‑digit EPS growth — the call and report will be the next major catalyst. Q1 conference call PR Newswire
• Neutral Sentiment: Analyst target movement is mixed: Goldman Sachs trimmed its target to $93 (still above current price), producing a modest negative signal compared with the other buy-side notes. Goldman Sachs/AmericanBankingNews
• Negative Sentiment: Investor litigation notices: Multiple law firms (RGRD, Rosen, Bronstein, Faruqi & Faruqi) are soliciting Boston Scientific investors for a securities class action tied to a July 23, 2025–Feb 3, 2026 class period — heightened legal risk and potential distraction for management. Class action GlobeNewswire

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Scotia Capital Inc. increased its holdings in Boston Scientific by 0.7% during the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider's stock valued at $1,621,000 after purchasing an additional 104 shares in the last quarter. West Family Investments Inc. increased its holdings in Boston Scientific by 163.2% during the 2nd quarter. West Family Investments Inc. now owns 6,285 shares of the medical equipment provider's stock valued at $675,000 after purchasing an additional 3,897 shares in the last quarter. Legacy Capital Wealth Partners LLC raised its position in Boston Scientific by 10.4% in the 2nd quarter. Legacy Capital Wealth Partners LLC now owns 3,725 shares of the medical equipment provider's stock valued at $400,000 after purchasing an additional 351 shares during the last quarter. Finally, VestGen Advisors LLC boosted its stake in Boston Scientific by 116.1% in the second quarter. VestGen Advisors LLC now owns 17,974 shares of the medical equipment provider's stock worth $1,929,000 after purchasing an additional 9,656 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 7.3%

The company has a market cap of $95.26 billion, a P/E ratio of 33.26, a PEG ratio of 1.07 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm has a fifty day moving average price of $77.45 and a 200 day moving average price of $90.61.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm's quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.